Form 4/A for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2021-12-07 00:00:00 ET · period of report 2021-08-09 · accession 0001213900-21-063945 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2021-12-07 | 2021-08-09 | ORMP | KIDRON NADAV | Pres, CEO, Dir, 10% | S - Sale | $20.11 | -220.0K | 738.2K | -23% | -$4.42M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-09 | S | D | 220,000 | $20.11 | 738,209 | D | — | — | (F1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021. (F2) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021. (F3) This amendment is being filed to correct an administrative error in Form 4 filed by Mr. Kidron, which reported that 648,573 shares of common stock are beneficially owned by him following the reported transaction. Mr. Kidron beneficially owned 738,209 shares of common stock following the reported transaction. |